Alnylam Pharmaceuticals, Inc. (LON: 0HD2)
London
· Delayed Price · Currency is GBP · Price in USD238.33
-6.27 (-2.56%)
Dec 23, 2024, 6:17 PM BST
Alnylam Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 29, 2024 | Dec '23 Dec 30, 2023 | Dec '22 Dec 30, 2022 | Dec '21 Dec 30, 2021 | Dec '20 Dec 30, 2020 | Dec '19 Dec 30, 2019 | 2018 - 2014 |
| Net Income | -332.26 | -440.24 | -1,131 | -852.82 | -858.28 | -886.12 | Upgrade
|
| Depreciation & Amortization | 101.19 | 97.03 | 85.55 | 89.69 | 74.44 | 54.37 | Upgrade
|
| Loss (Gain) From Sale of Investments | 2.09 | 16.94 | 33.31 | -55.7 | -54.04 | -11.29 | Upgrade
|
| Stock-Based Compensation | 222.43 | 221.68 | 230.65 | 165.72 | 139.87 | 174.84 | Upgrade
|
| Other Operating Activities | 196.19 | 197.98 | 275.92 | 174.24 | 95.76 | -12.61 | Upgrade
|
| Change in Accounts Receivable | -23.17 | -87.94 | -45.6 | -101.8 | -56.24 | -24.24 | Upgrade
|
| Change in Inventory | 24.73 | 18.37 | -34.14 | -26.42 | -35.43 | -32.41 | Upgrade
|
| Change in Accounts Payable | 114.53 | 80.84 | 191.77 | 88.24 | 143.73 | 92.35 | Upgrade
|
| Change in Unearned Revenue | -201.19 | 55.02 | -65.91 | -50.4 | -43.97 | 392.25 | Upgrade
|
| Change in Other Net Operating Assets | -47.98 | -55.53 | -81.68 | -72.45 | -20.81 | -25.58 | Upgrade
|
| Operating Cash Flow | 56.56 | 104.16 | -541.27 | -641.69 | -614.96 | -278.43 | Upgrade
|
| Capital Expenditures | -40.49 | -62.21 | -72.06 | -76.37 | -70.36 | -140.16 | Upgrade
|
| Investment in Securities | -244.89 | -269.7 | 254.61 | -192.56 | -333.96 | -300.52 | Upgrade
|
| Other Investing Activities | -19.2 | -4.44 | -13.19 | -4.36 | -31.2 | 23 | Upgrade
|
| Investing Cash Flow | -304.59 | -336.35 | 169.35 | -273.3 | -435.52 | -417.68 | Upgrade
|
| Long-Term Debt Issued | - | - | 1,016 | 500 | 200 | - | Upgrade
|
| Long-Term Debt Repaid | - | - | -880.72 | - | - | - | Upgrade
|
| Net Debt Issued (Repaid) | - | - | 135.39 | 500 | 200 | - | Upgrade
|
| Issuance of Common Stock | 297.57 | 147.46 | 259.36 | 246.27 | 299.98 | 853.18 | Upgrade
|
| Other Financing Activities | 4.82 | 24.67 | 31 | 500.85 | 495 | -30 | Upgrade
|
| Financing Cash Flow | 302.39 | 172.13 | 425.75 | 1,247 | 994.98 | 823.18 | Upgrade
|
| Foreign Exchange Rate Adjustments | 12.93 | 6.39 | -7.43 | -9.02 | 4.92 | -0.08 | Upgrade
|
| Net Cash Flow | 67.29 | -53.67 | 46.4 | 323.11 | -50.58 | 127 | Upgrade
|
| Free Cash Flow | 16.06 | 41.95 | -613.33 | -718.07 | -685.32 | -418.58 | Upgrade
|
| Free Cash Flow Margin | 0.77% | 2.29% | -59.12% | -85.05% | -139.05% | -190.48% | Upgrade
|
| Free Cash Flow Per Share | 0.13 | 0.34 | -5.04 | -6.06 | -5.96 | -3.83 | Upgrade
|
| Cash Interest Paid | 60.69 | 32.12 | 45.24 | 24.66 | - | 0.17 | Upgrade
|
| Levered Free Cash Flow | 309.57 | 146.53 | -403.26 | 97.11 | -777.14 | -415.84 | Upgrade
|
| Unlevered Free Cash Flow | 393.46 | 222.29 | -305.78 | 186.5 | -724.33 | -415.84 | Upgrade
|
| Change in Net Working Capital | -227.91 | -142.15 | 59.25 | -450.37 | 350.5 | -82.25 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.